Pramlintide vs Rusfertide
Overview
Pramlintide and Rusfertide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Pramlintide and Rusfertide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Pramlintide | Rusfertide | |
|---|---|---|
| Category | Weight Management & Metabolic | Weight Management & Metabolic |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 60-120 mcg | 19-108 mg |
| Frequency | with meals | once weekly, subcutaneous |
| Reported benefits | Reduced post-meal glucose, weight loss, appetite control | In the Phase 3 VERIFY trial, adding rusfertide to standard-of-care therapy allowed 76.9% of participants to achieve hematocrit control without phlebotomy during weeks 20-32, compared with 32.9% on placebo plus standard of care. Reported benefits are specific to polycythemia vera erythrocytosis management and have not been studied for other conditions. |
| Reported side effects | Nausea, hypoglycemia risk with insulin | Injection-site reactions (56%) and anemia (16%) were the most common adverse events in clinical trials; labeled warnings include thrombocytosis and embryo-fetal toxicity. |
Key differences
Primary use. Pramlintide is categorised under Weight Management & Metabolic, while Rusfertide falls under Weight Management & Metabolic. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Pramlintide: FDA-approved. Rusfertide: FDA-approved.
Dosing. Pramlintide is typically dosed at 60-120 mcg (with meals). Rusfertide is typically dosed at 19-108 mg (once weekly, subcutaneous).
Can you stack them?
Some protocols combine peptides, but stacking Pramlintide and Rusfertide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Pramlintide and Rusfertide?
- Pramlintide and Rusfertide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status. Pramlintide is FDA-approved for one or more indications, whereas Rusfertide is FDA-approved for one or more indications.
- What is Pramlintide used for?
- Amylin analog for diabetes.
- What is Rusfertide used for?
- A once-weekly injectable hepcidin-mimetic peptide FDA-approved to treat erythrocytosis in adults with polycythemia vera.
- Can you take Pramlintide and Rusfertide together?
- Some users combine peptides within a single protocol, but stacking Pramlintide and Rusfertide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Pramlintide or Rusfertide FDA-approved?
- Pramlintide is FDA-approved for one or more indications. Rusfertide is FDA-approved for one or more indications.
Read the full articles
- Pramlintide — full monograph: mechanism, research, dosing & references
- Rusfertide — full monograph: mechanism, research, dosing & references